Biotech | 17 November 2021
World’s first Donepezil patch to treat Alzheimer approved in South Korea
Launching in 2022, its availability will be expanded to the global market
Launching in 2022, its availability will be expanded to the global market
The interim data combines three mRNAs into one therapy injected directly into the tumour
The company expects to begin shipping this product before the end of its fiscal first quarter, ending December 31, 2021
A final decision regarding the approval of Ronapreve is expected from the European Commission shortly
Bioanalytical approach to accelerate development efforts in the identification of compounds that can treat chlorine or sulfur mustard injuries
Positive results reinforce the improved efficacy seen with Opdivo-based treatments in four Phase 3 clinical trials in earlier-stage cancers, including lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma
In the overall study population through Day 28, no deaths were reported in patients who received Paxlovid as compared to 10 deaths in patients who received placebo
The new manufacturing facility will be built at a subsidiary of Adcock Ingram and will commence operation in March 23
All modules required for regulatory review of Novavax vaccine, including CMC data, are now complete for WHO
The product is synthetically developed as compared to the current process of drawing the same from blood plasma and is backed by a granted global patent
The collaboration will combine Metagenomi’s next-generation CRISPR-based and other novel gene editing systems with Moderna’s mRNA and LNP technologies
Cortrophin gel is purified corticotropin (ACTH), an important treatment option for patients struggling with certain chronic autoimmune disorders. It acquired the NDA for cortrophin gel from Merck & Co. in 2016
Expertise in exosomes isolation and characterization will drive innovation in this field
The vaccine can be stored at 2 to 8 degrees celsius and traditional cold chain capabilities will suffice
The agreement sharpens the company’s focus on priority medicines in respiratory & immunology portfolio
The release of this batch will secure the supply for hospitals and cancer centres that are involved in the clinical trials managed by the company
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in India to the U.S. population
Subscribe To Our Newsletter & Stay Updated
